Volume 14, Issue 3 ( September 2022 2022)                   Iranian Journal of Blood and Cancer 2022, 14(3): 11-15 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hamidfar M, Sheikhpour E, Akhavan Tafti M, Daneshmand F, Abedinzadeh M. Evaluation of the prognostic value of CD117 and CK20 biomarkers in urinary bladder carcinoma. Iranian Journal of Blood and Cancer 2022; 14 (3) :11-15
URL: http://ijbc.ir/article-1-1240-en.html
Evaluation of the prognostic value of CD117 and CK20 biomarkers in urinary bladder carcinoma
Mahdieh Hamidfar1 , Elnaz Sheikhpour * 2, Mahmood Akhavan Tafti3 , Fateme Daneshmand1 , Mehdi Abedinzadeh4
1- Payam Noor Uni
2- Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , r.sheikhpour@yahoo.com
3- shahid sadoughi uni
4- Shahid Sadoughi University
Abstract:   (1011 Views)

Background: Over-expression of CD117 and cytokeratin 20 (CK20) is seen in many malignancies. Given that few studies have been conducted regarding the role of these biomarkers in the etiology of bladder tumours, this study aimed to evaluate the prognostic value of CD117 and CK 20 biomarkers in the benign and malignant tumours of urinary bladder carcinoma.
Methods: This case-control study was conducted on 62 bladder tumours (17 benign tumours and 45 malignant tumours). The immunohistochemistry technique was used to assess CK20 and CD117 biomarkers in tumour samples.
Results: There is no significant difference between benign and malignant groups in terms of CD117 (p=0.094). No significant difference was observed between expression of CD117 in terms of grade (p=0.184). However, a significant difference was observed between benign and malignant groups in terms of CK20 expression (p=0.022). Moreover, a significant difference was observed between CK20 expression in terms of grade (p=0.009). In addition, a significant difference was observed between the age of patients considering grade (p<0.047).
Conclusion: The results of the current study supported the role of CK20 in the carcinogenesis of urinary bladder carcinoma. Moreover, it seems that CK20 expression may be considered as a poor prognostic parameter in transitional bladder carcinoma. Furthermore, these findings indicated that patients with higher age had higher grade. In addition, assessment of CD117 expression did not play a main role in tumour progression. Therefore, it is not recommended for bladder tumours.

Keywords: Bladder cancer, CD117, Cytokeratin 20
Full-Text [PDF 404 kb]   (719 Downloads)    
: Original Article | Subject: Adults Hematology & Oncology
Received: 2022/04/3 | Accepted: 2022/08/12 | Published: 2022/09/19
References
1. Metts M. Bladder cancer. A review of diagnosis and management. J National Medical association. 2000; 92(6): 285-294. [DOI:10.1093/jnci/92.4.294]
2. Ye F, Wang l, Castillo-Martin M, McBride R1, Galsky M. Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol. 2014; 2(1): 1-14.
3. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29. [DOI:10.3322/caac.21208]
4. NouraniH. Low-dose Gemcitabine and Carboplatin as a Good Palliation for Local Symptoms in Advanced Transitional Cell Carcinoma of Bladder. Iranian J Blood Cancer. 2009; 1(3):119-120.
5. Sanli O, Dobruch J, Knowles M, Burger M, , Alemozaffar M. Bladder cancer. 2017; 13-17. [DOI:10.1038/nrdp.2017.22]
6. Freedman N, Silverman D, R Hollenbeck A, Schatzkin A, Abnet Ch. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306(7): 737-745. [DOI:10.1001/jama.2011.1142]
7. D'Avanzo B, Negri E, La Vecchia C, Gramenzi A, Bianchi C, Franceschi S, Boyle P. Cigarette smoking and bladder cancer. Eur J Cancer. 1990; 26(6): 714-8. [DOI:10.1016/0277-5379(90)90124-C]
8. Neal D. Freedman, Debra T. Silverman, ScD, ScM; Albert R. Hollenbeck. Association Between Smoking and Risk of Bladder Cancer Among Men and Women. JAMA. 2011; 306(7): 737-745. [DOI:10.1001/jama.2011.1142]
9. Tobacco Smoke and Involuntary Smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon, France: IARC; 2004. 83.
10. Silverman DT, Devesa SS, Moore LE, Rothman N. Bladder cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York, NY: Oxford University Press; 2006:1101-1127. [DOI:10.1093/acprof:oso/9780195149616.003.0058]
11. Masaoka Keitaro H, Hidemi M, Kenji I. Cigarette smoking and bladder cancer risk: an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Japanese J Clin Oncol. 2016; 46 (3): 273-283. [DOI:10.1093/jjco/hyv188]
12. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol Forthcoming. 2015; 1-10.
13. Chung K. The etiology of bladder cancer and its prevention. J Cancer Sci Ther. 2013; 5(10): 346-361 [DOI:10.4172/1948-5956.1000226]
14. Taleb S. C kit and Bcl2 in bladder carcinoma:An immunohistochemical study. AAMJ. 2013; 11(1): 214-227.
15. Shams T and Metawea M, Overexpression of C-KIT in Schistosomal Urinary Bladder Carcinoma. Med. J. Cairo Univ. 2011; 79(1): 449-455.
16. Raheem S.A, Saied A.N, Shaer R, Mustafa O, Ali A. The Role of CK20, p53 and p63 in differentiation of some urothelial lesions of urinary bladder, immunohistochemical study. Open J Pathol. 2014; 181-193. [DOI:10.4236/ojpathology.2014.44024]
17. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. European J Cancer. 2002; 38(6): 758-763. [DOI:10.1016/S0959-8049(02)00008-4]
18. Lopez-Beltran A, Sauter G, Gasser T, Tumours of the urinary system. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds), Pathology and genetics of tumours of the urinary system and male genital organs, World Health Organization Classification of Tumours, IARC Press, Lyon, 2004; 89- 154.
19. Jiang J, Ulbright TM, Younger C, Sanchez K, Bostwick DG, Koch MO, Eble JN, Cheng L. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med. 2001;125(7): 921-3. [DOI:10.5858/2001-125-0921-CACIPU]
20. Hammam O, Wishahiz M, Khalil H, El Ganzouri H, Badawy M, Elkhquly A, Elesaily K. Expression of cytokeratin 7, 20, 14 in urothelial carcinoma and squamous cell carcinoma of the Egyprian urinary bladder cancer. J Egypt Soc Parasitol. 2014; 44(3): 733-40. https://doi.org/10.21608/jesp.2014.90369 [DOI:10.12816/0007876]
21. Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol. 1998.160(6): 1971-4. [DOI:10.1016/S0022-5347(01)62215-8]
22. Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer. 1998; 82: 349-54. https://doi.org/10.1002/(SICI)1097-0142(19980115)82:2<355::AID-CNCR16>3.0.CO;2-Y [DOI:10.1002/(SICI)1097-0142(19980115)82:23.0.CO;2-Y]
23. Han A. Coexpression of cytokeratins 7 and 20 confirms urothelial carcinoma presenting as an intrarenal tumour. Cancer. 2000; 4-9. https://doi.org/10.1002/(SICI)1097-0142(19991201)86:11<2327::AID-CNCR21>3.0.CO;2-D [DOI:10.1002/(SICI)1097-0142(19991201)86:113.0.CO;2-D]
24. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase‐polymerase chain reaction. Br J Cancer. 1995; 71: 278-81. [DOI:10.1038/bjc.1995.56]
25. Harnden P, Allam A, Joyce AD, Patel A, Selby P, Southgate J. Cytokeratin 20 expression by non‐invasive transitional cell carcinomas: potential for distinguishing recurrent from non‐recurrent disease. Histopathology. 1995; 27: 169-74. [DOI:10.1111/j.1365-2559.1995.tb00025.x]
26. Aliza Z, Gad N, Yoram D, Alon H, Tuvia H, Gideon SY, Edward Y, Lea RW. Expression of C-KIT receptor in transitional cell carcinoma of urinary bladder and its correlation with clinicopathological variables Conexunimedicale 2009; 16.
27. Pan C, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble GN, Koch MO, et al. kit expression in small cell carcinoma of the Urinary bladder: prognostic and therapeutic implications. Modern Pathol. 2005; 18: 320-323. [DOI:10.1038/modpathol.3800318]
28. Zigeuner R, Ratschek M, Langer C. Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas. Bju International. 2005; 5 - 31. [DOI:10.1111/j.1464-410X.2005.05290.x]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb